TY - JOUR T1 - Assessing the heterogeneity in the transmission of infectious diseases from time series of epidemiological data JF - medRxiv DO - 10.1101/2022.02.21.22271241 SP - 2022.02.21.22271241 AU - Günter Schneckenreither AU - Lukas Herrmann AU - Rafael Reisenhofer AU - Nikolas Popper AU - Philipp Grohs Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/03/01/2022.02.21.22271241.abstract N2 - Structural features and the heterogeneity of disease transmissions play an essential role in the dynamics of epidemic spread. But these aspects can not completely be assessed from aggregate data or macroscopic indicators such as the effective reproduction number. We propose an index of effective aggregate dispersion (EffDI) that indicates the significance of infection clusters and superspreading events in the progression of outbreaks by carefully measuring the level of stochasticity in time series of reported case numbers. This allows to detect the transition from predominantly clustered spreading to a diffusive regime with diminishing significance of singular clusters, which can be decisive for the future progression of outbreaks and relevant in the planning of containment measures. We evaluate EffDI for SARS-CoV-2 case data in different countries and compare the results with a quantifier for the socio-demographic heterogeneity in disease transmissions in a case study to substantiate that EffDI qualifies as a measure for the heterogeneity in transmission dynamics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementR.R. gratefully acknowledges support from the Austrian Science Fund (FWF M 2528).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTime series of reported case numbers of COVID-19 are made available by the Center for Systems Science and Engineering at Johns Hopkins University in an online repository. Parameters of the statistical distributions of disease intervals (published in literature or generated during the current study) are provided in the supplementary material with references to the sources where applicable. Data that was used particularly in the Austrian case study was provided to us by the Austrian Agency for Health and Food Safety under a restrictive license. The results of statistical evaluations are however available in the supplementary material. Demographic data for Austria is made available by Statistics Austria. ER -